CIBER DE ENFERMEDADES RESPIRATORIAS (CIBERES)

What CIBER DE ENFERMEDADES RESPIRATORIAS (CIBERES) does

CIBERES (Centro de Investigación en Red de Enfermedades Respiratorias) is a Spanish public biomedical research consortium and one of 13 thematic areas within the CIBER network, operated under the Instituto de Salud Carlos III (ISCIII) and the Spanish Ministry of Science and Innovation. It coordinates more than 500 research groups and over 6,000 researchers across more than 100 hospitals, research centers, universities, and foundations to advance the prevention, diagnosis, and treatment of respiratory diseases. The consortium is structured around four research programs — chronic respiratory diseases (COPD, asthma, sleep apnea), infectious respiratory diseases (pneumonia, tuberculosis, host-pathogen interactions), diffuse respiratory diseases (pulmonary fibrosis, pulmonary hypertension, acute lung injury), and COVID/other respiratory viruses — supplemented by cross-cutting programs in internationalization, training, and technology/know-how transfer.

Research is delivered through flagship collaborative projects including P-NEXT (multi-omics and AI-driven pneumonia characterization combining genomics, transcriptomics, epigenomics, GWAS, proteomics, metabolomics, lipidomics, and machine learning), RESPICHALLENGE (antimicrobial resistance addressed via synthetic biology platforms for antibacterial development and drug delivery), and MAPS (biomarker discovery and diagnostic tools for COPD). The Plataforma Biobanco Pulmonar provides a centralized pulmonary biobank supporting sample access across the network. CIBERES does not commercialize products or services; its activities are funded through public institutional grants from ISCIII, with supplementary industry sponsorship from pharmaceutical and diagnostics partners (AstraZeneca, Boehringer Ingelheim, MSD, Advanz Pharma, Biomerieux) and foundation support (Fundación Banco Sabadell). Findings are disseminated through scientific publications (including in high-impact journals such as The Lancet Microbe), participation in congresses such as ERS and ATS, and integration into clinical practice within the Spanish National Health System.

Name

CIBER DE ENFERMEDADES RESPIRATORIAS (CIBERES)

Legal name

CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED

Website

https://ciberes.org

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

CIBERES is a Spanish public biomedical research consortium under ISCIII, coordinating 500+ research groups and 6,000+ researchers across 100+ institutions to advance prevention, diagnosis, and treatment of respiratory diseases.

Ownership category

akta.pro rank

Product category

Respiratory Disease Research

NAICS

Professional, Scientific, and Technical Services (541), Other Scientific and Technical Consulting Services (54169)

akta.pro primary industry

Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry) (HLAFAKAJ)

akta.pro secondary industries

Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

Keywords

• Respiratory disease research
• Biomedical research network
• Pulmonary biobank
• Multi-omics research
• Infectious respiratory diseases

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Public Institutional Funding: CIBERES receives public funding from the Instituto de Salud Carlos III (ISCIII) and the Spanish Ministry of Science and Innovation. The consortium model connects more than 100 institutions including hospitals, research centers, universities and foundations working in network to achieve excellence in research.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

CIBERES is a Spanish biomedical research consortium that coordinates collaborative research on respiratory diseases across hospitals, universities, and research centers. It operates four thematic research programs (chronic, infectious, diffuse lung diseases, and COVID-19/respiratory viruses) along with cross-cutting platforms including a pulmonary biobank, training, technology transfer, and internationalization programs.

Product overview

CIBERES operates as a network-based biomedical research consortium (Centro de Investigación Biomédica en Red) focused on respiratory diseases. The organization is structured around four main research programs (Chronic Respiratory Diseases, Infectious Respiratory Diseases, Diffuse Respiratory Diseases, and COVID/respiratory viruses), supplemented by cross-cutting programs in internationalization, training, and technology transfer. Key collaborative research projects include P-NEXT (pneumonia), RESPICHALLENGE (antimicrobial resistance), and MAPS (COPD), which employ next-generation sequencing, multi-omics, and AI-based analysis. The consortium also offers a Pulmonary Biobank Platform and various funding mechanisms through competitive calls. The portfolio integrates basic research, translational research, and clinical applications across respiratory disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Programa de Enfermedades Respiratorias Crónicas
• Programa de Enfermedades Respiratorias Infecciosas
• Programa de Enfermedades Respiratorias Difusas
• Programa COVID y otros virus respiratorios
• Plataforma Biobanco Pulmonar
• Programa de Formación
• Oferta Tecnológica y Know-How
• Convocatorias / Proyectos Estratégicos (P-NEXT, RESPICHALLENGE, MAPS)

Quantifiable outcome

• CIBERES publishes research in high-impact journals including The Lancet Microbe, with recent publications advancing understanding of pneumococcal serotype virulence mechanisms

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• AstraZenecacoreStrategic or Co-development Partner · 19 June 2026AstraZeneca and CIBER signed an agreement to boost respiratory disease research in Spain. The partnership aims to foster a collaborative environment promoting biomedical research and innovative initiatives in respiratory diseases. As a first initiative, they will hold a hackathon on respiratory diseases between October 1-3, 2026 at the AstraZeneca Global Hub in Barcelona, bringing together experts from different disciplines to address scientific and technological challenges using AI and data science.
• Fundación Banco SabadellcoreStrategic or Co-development Partner · 1 January 2026Fundación Banco Sabadell collaborates with CIBER on a training program for 20-30 researchers in early career stages, particularly women, strengthening transversal competencies in leadership, knowledge transfer, and scientific communication.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 1 January 2026Boehringer Ingelheim sponsors the Awards for Best Communications at the II CIBER Young Scientific Staff Days 2026, recognizing excellence, innovation, and scientific impact of young researchers across different CIBER areas.
• MSDsupportingStrategic or Co-development Partner · 14 April 2025MSD sponsored the I Jornada del Programa de Enfermedades Respiratorias Infecciosas de CIBERES held at the Centro de Investigación Biomédica de Aragón (CIBA) in Zaragoza, bringing together 65 researchers from four CIBER areas.
• Advanz PharmasupportingStrategic or Co-development Partner · 14 April 2025Advanz Pharma sponsored the I Jornada del Programa de Enfermedades Respiratorias Infecciosas de CIBERES.
• BiomerieuxsupportingStrategic or Co-development Partner · 14 April 2025Biomerieux sponsored the I Jornada del Programa de Enfermedades Respiratorias Infecciosas de CIBERES.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Others

• European Respiratory Society (ERS): Pan-European professional society that CIBERES researchers actively participate in for congresses, guidelines, and collaborative studies. Comparable as an ecosystem-level enabler of respiratory research networks, though not a direct research-producing competitor.

Broad incumbents

• NHLBI (National Heart, Lung, and Blood Institute): US NIH institute that funds and coordinates large-scale respiratory and cardiovascular research networks. Operates a comparable model of multi-center translational programs with shared cohorts and biobanks, but at vastly greater scale and as part of the broader NIH ecosystem rather than a single-disease focus.
• INSERM: France's national institute for health and medical research, a much larger public research organization covering all biomedical domains including respiratory medicine. Comparable in its public-mission, multi-site network model and government funding structure, though broader in scope than CIBERES's respiratory focus.
• UK Respiratory Research Collaborative / MRC Centre框架: UK Medical Research Council funds multi-site respiratory research programs and training centers with similar translational and capacity-building objectives. Comparable as a publicly funded national research funder, though not organized as a single-disease consortium like CIBERES.

Regional players

• Institut de Recherche en Santé Respiratoire des Pays de la Loire (IRSR): French regional respiratory research cluster focused on chronic and infectious lung diseases. Comparable in its network-based research model and public funding orientation, but operates regionally rather than at CIBERES's national-Spanish scale.

Direct peers

• German Center for Lung Research (DZL): Germany's federal pulmonary research network integrating multiple university sites and translational programs across major lung diseases (COPD, asthma, pneumonia, fibrosis). DZL is the closest international structural analogue to CIBERES as a publicly funded, multi-site respiratory research consortium with industry partnerships.
• CIBERINFEC (Infectious Diseases area of CIBER): A sister thematic area within the same CIBER consortium under ISCIII, also focused on infectious disease research with overlapping investigators and infrastructure. Operates under identical governance and funding mechanisms, sharing platforms such as the Biobank and training programs with CIBERES.

Emerging players

• Karolinska Institutet Respiratory Research Group: Leading Swedish academic medical center with strong respiratory research programs in chronic and infectious lung disease. Comparable as a top-tier European academic research group, though operating as a single institution rather than a network model like CIBERES.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CIBER_ISCIII
• Instagraminstagram.com/consorcio_ciber
• LinkedInlinkedin.com/company/ciber-de-enfermedades-respiratorias-ciberes-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CIBER DE ENFERMEDADES RESPIRATORIAS (CIBERES)